Design of greener drugs: aligning parameters in pharmaceutical R&D and drivers for environmental impact
Research output: Journal contributions › Scientific review articles › Research
Standard
In: Drug Discovery Today, Vol. 29, No. 7, 104022, 01.07.2024.
Research output: Journal contributions › Scientific review articles › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Design of greener drugs
T2 - aligning parameters in pharmaceutical R&D and drivers for environmental impact
AU - Vidaurre, Rodrigo
AU - Bramke, Irene
AU - Puhlmann, Neele
AU - Owen, Stewart F.
AU - Angst, Daniela
AU - Moermond, Caroline
AU - Venhuis, Bastiaan
AU - Lombardo, Anna
AU - Kümmerer, Klaus
AU - Sikanen, Tiina
AU - Ryan, Jim
AU - Häner, Andreas
AU - Janer, Gemma
AU - Roggo, Silvio
AU - Perkins, Alison Nimrod
N1 - Publisher Copyright: © 2024 The Authors
PY - 2024/7/1
Y1 - 2024/7/1
N2 - Active pharmaceutical ingredients (APIs) in the environment, primarily resulting from patient excretion, are of concern because of potential risks to wildlife. This has led to more restrictive regulatory policies. Here, we discuss the ‘benign-by-design’ approach, which encourages the development of environmentally friendly APIs that are also safe and efficacious for patients. We explore the challenges and opportunities associated with identifying chemical properties that influence the environmental impact of APIs. Although a straightforward application of greener properties could hinder the development of new drugs, more nuanced approaches could lead to drugs that benefit both patients and the environment. We advocate for an enhanced dialogue between research and development (R&D) and environmental scientists and development of a toolbox to incorporate environmental sustainability in drug development.
AB - Active pharmaceutical ingredients (APIs) in the environment, primarily resulting from patient excretion, are of concern because of potential risks to wildlife. This has led to more restrictive regulatory policies. Here, we discuss the ‘benign-by-design’ approach, which encourages the development of environmentally friendly APIs that are also safe and efficacious for patients. We explore the challenges and opportunities associated with identifying chemical properties that influence the environmental impact of APIs. Although a straightforward application of greener properties could hinder the development of new drugs, more nuanced approaches could lead to drugs that benefit both patients and the environment. We advocate for an enhanced dialogue between research and development (R&D) and environmental scientists and development of a toolbox to incorporate environmental sustainability in drug development.
KW - bioaccumulation
KW - chemical mobility
KW - ecotoxicity
KW - environmentally benign
KW - human health
KW - persistence
KW - safe and sustainable by design SSbD
KW - Chemistry
UR - http://www.scopus.com/inward/record.url?scp=85193784874&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/04784453-329a-31e7-88eb-1401da7c022f/
U2 - 10.1016/j.drudis.2024.104022
DO - 10.1016/j.drudis.2024.104022
M3 - Scientific review articles
C2 - 38750927
AN - SCOPUS:85193784874
VL - 29
JO - Drug Discovery Today
JF - Drug Discovery Today
SN - 1359-6446
IS - 7
M1 - 104022
ER -